Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotics, fecal microbiota transplantation, and combined therapy for inflammatory bowel disease
jRCTs031180415Completed
- Sponsor
- Kyowa Kirin
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of amoxicillin, fosfomycin and metronidazole in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (3 arms), sponsored by Kyowa Kirin. Primary endpoints: Safety, Efficacy and 2 more. Started Feb 2017; status: completed.
02
Drugs
amoxicillinfosfomycinmetronidazole
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on jRCTs031180415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180415.